409 Illinois Street
About FibroGen, Inc.
FibroGen, Inc., headquartered in San Francisco, with subsidiary offices in Beijing and Shanghai, is a leading biopharmaceutical company discovering and developing a pipeline of first-in-class therapeutics. The company applies its pioneering expertise in hypoxia-inducible factor (HIF), connective tissue growth factor (CTGF) biology, and clinical development to advance innovative medicines for the treatment of anemia, fibrotic disease, and cancer. Roxadustat, the company's most advanced product candidate, is an oral small molecule inhibitor of HIF prolyl hydroxylase activity, completing worldwide Phase 3 clinical development for the treatment of anemia in chronic kidney disease (CKD), with a New Drug Application (NDA) currently under review in China by the State Drug Administration (SDA). Roxadustat is in Phase 3 clinical development in the U.S. and Europe and in Phase 2/3 development in China for anemia associated with myelodysplastic syndromes (MDS). Pamrevlumab, an anti-CTGF human monoclonal antibody, is advancing towards Phase 3 clinical development for the treatment of idiopathic pulmonary fibrosis (IPF) and pancreatic cancer, and is currently in a Phase 2 trial for Duchenne muscular dystrophy (DMD). FibroGen is also developing a biosynthetic cornea in China. For more information, please visit www.fibrogen.com.
143 articles with FibroGen, Inc.
New Roxadustat Data in Anemia of Chronic Kidney Disease to be Released at ASN Kidney Week 2020 Reimagined
42 abstracts featuring additional insights into roxadustat and anemia of chronic kidney disease to be presented
FibroGen to Present New Efficacy and Safety Analyses from Roxadustat Global Phase 3 Program at American Society of Nephrology Kidney Week 2020 Reimagined
Late-breaking abstracts explore cardiovascularoutcomes of patients with anemia in chronic kidney disease(CKD) treated with roxadustat, including associations with achieved hemoglobin levels and risk of Major Adverse Cardiovascular Events (MACE) and MACE+
New Ventures Funds has launched a new corporate brand identity and changed its name to Scientia Ventures. The new website for the firm can be found at: www.scientiavc.com.
FibroGen, Inc. announced the appointment of Percy Carter, MBA, PhD, to the newly-created position of Chief Scientific Officer, where he will lead FibroGen’s research efforts, leveraging more than 20 years of global biopharmaceutical leadership and experience.
FibroGen, Inc. (NASDAQ: FGEN) today announced that Enrique Conterno, Chief Executive Officer, will participate in fireside chats at the following virtual healthcare conferences: Citigroup 15th Annual BioPharma Conference on September 9, 2020 at 2:25 PM Eastern Time Morgan Stanley 18 th Annual Global Healthcare Conference on September 16, 2020 at 3:30 PM Eastern Time A live audio webcast will be available on the “Events & Presentation
FibroGen Announces First Patient Enrolled in Pamrevlumab Phase 3 Clinical Trial in Patients with Duchenne Muscular Dystrophy
FibroGen, Inc. (NASDAQ: FGEN) announced the initiation of LELANTOS, a Phase 3, randomized, double-blind, placebo-controlled trial of pamrevlumab or placebo in combination with systemic corticosteroids in patients with non-ambulatory Duchenne muscular dystrophy (DMD). The primary objective of this global study is to evaluate the effect of pamrevlumab on muscle function in patients with DMD. Approximately 90 patients will be randomized 1:1 to rec
FibroGen, Inc. reported financial results for the second quarter of 2020 and provided an update on the company’s recent developments.
Appoints Ben Cravatt, Ph.D., Professor and the Norton B. Gilula Chair of Chemical Biology in the Department of Chemistry at The Scripps Research Institute
FibroGen, Inc. will announce its second quarter 2020 financial results on Thursday, August 6 after the market close.
FibroGen Announces First Patient Enrolled in Pamrevlumab Clinical Trial in Patients Hospitalized in U.S. with Acute COVID-19
FibroGen, Inc. announced the initiation of a randomized, double-blind, placebo-controlled Phase 2 Study investigating the efficacy and safety of pamrevlumab in hospitalized patients with acute coronavirus 2019 infection.
FibroGen, Inc. announced the appointment of Thane Wettig to the newly-created position of Chief Commercial Officer, where he will lead FibroGen’s commercialization efforts, leveraging more than 30 years of global biopharmaceutical leadership and experience.
FibroGen, Inc. (NASDAQ:FGEN) announced data from three roxadustat clinical trials, including the Phase 3 DOLOMITES study evaluating roxadustat for treatment of anemia in non-dialysis-dependent CKD patients compared to darbepoetin alfa, and ophthalmology findings from a Japan Phase 3 study evaluating roxadustat compared to darbepoetin alfa in patients on hemodialysis
FibroGen Announces First Patient Enrolled in Pamrevlumab Clinical Trial in Patients Hospitalized in Italy with Severe COVID-19
Additional Pamrevlumab Clinical Trials Planned in Patients Hospitalized in United States with Severe COVID-19
Check out this article for the impacts that Biotech Bay companies are experiencing due to COVID-19.
FibroGen, Inc. announced that Enrique Conterno, Chief Executive Officer, will participate in fireside chats at the following virtual healthcare conferences
FibroGen, Inc. (NASDAQ: FGEN) will participate in the Bank of America Securities 2020 Health Care Conference that is being held virtually on May 12-14, 2020. Enrique Conterno, Chief Executive Officer, will participate in a fireside chat at 11:00 AM Eastern Time on Thursday, May 14. A live audio webcast will be available on the “Events & Presentations” section of the FibroGen website at www.fibrogen.com. A replay of the fireside chat will be a
FibroGen, Inc. reported financial results for the first quarter of 2020 and provided an update on the company’s recent developments.
FibroGen, Inc. (NASDAQ: FGEN) will announce its first quarter 2020 financial results on Thursday, May 7, 2020. FibroGen will also conduct a conference call on that day at 5:00 p.m. ET (2:00 p.m. PT) with the investment community to further detail the company's corporate and financial performance. Conference Call and Audio Webcast Interested parties may access a live audio webcast of the conference call via the FibroGen website at https:/
FibroGen, Inc. announced that the United Kingdom’s High Court of Justice has held certain patents1 relating to methods of using hypoxia-inducible factor prolyl hydroxylase inhibitors to be invalid.
FibroGen, Inc. (NASDAQ: FGEN) today reported financial results for the fourth quarter and full year of 2019 and provided an update on the company’s recent development